Alone in the spotlight, Pfizer CEO Bourla swears pure intentions in the rush to develop a Covid-19 vaccine. But will the public believe it?

Now that Moderna has shifted expectations on pivotal data for its Covid-19 vaccine to some time just after the election and AstraZeneca has been stalled …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

Alone in the spotlight, Pfizer CEO Bourla swears pure intentions in the rush to develop a Covid-19 vaccine. But will the public believe it?

This article is available only to Premium subscribers

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Revolution’s KRAS drugs appear competitive in several lung cancer settings

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

AstraZeneca reports Phase 3 win for Imfinzi; Roche to build new manufacturing site in China

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi

Corvus' early-phase atopic dermatitis data prompt stock rally

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

Alone in the spot­light, Pfiz­er CEO Bourla swears pure in­ten­tions in the rush to de­vel­op a Covid-19 vac­cine. But will the pub­lic be­lieve it?

This article is available only to Premium subscribers

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

Alone in the spotlight, Pfizer CEO Bourla swears pure intentions in the rush to develop a Covid-19 vaccine. But will the public believe it?

Revolution’s KRAS drugs appear competitive in several lung cancer settings

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

AstraZeneca reports Phase 3 win for Imfinzi; Roche to build new manufacturing site in China

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi

Corvus' early-phase atopic dermatitis data prompt stock rally

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges